DrugInfoSys

Fenofibrate

Drug #1454

Fenofibrate is an antihyperlipidaemic drug, belongs to fibrates. It acts mainly by decreasing serum triglycerides; it has variable effects on LDL-cholesterol. Fenofibrate is used in hyperlipdaemias of type II a, II b, III, IV and V in patients who have not respond adequately to the dietand other appropriate measures. It may also reduce the risk of coronary heart disease events in those with low HDL-cholesterol or with raised triglycerides.

Primary Characteristics

Fenofibrate is also known as Fenofibrate (Micronized).

It is of Synthetic origin.

Molecular Weight: 360.8 · Solubility in Water: Insoluble · Solubility in Alcohol: slighty · Non-proprietary name: Fenofibrate.

Molecular structure of Fenofibrate

Pharmacokinetics

Absorption: Fenofibrate has an oral bioavailability is 75% (±15%), pre-systemic (first-pass) metabolism accounts for 50% (±50%).

Distribution: Fenofibrate has a volume of distribution is 0.89 l/kg. plasma protein binding is 99 %.

Elimination: plasma half-life is 22.1 hr, renal excretion is 65 %.

Advertisement

Indications

Contraindications

Fenofibrate is contraindicated in conditions like Gall stones, Liver diseases, Renal impairment, Hypersensitivity, Pregnancy.

Dosage

Fenofibrate's dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
300 mg300 mgEvery 24hPOInitial
300 mg300 mgEvery 24hPOAfter 2-3 months after arsaying serum lipids.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Fenofibrate in overdosage may give rise to further complications which include Hepatitis , Rhabdomyolysis .

Fenofibrate is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Decrease in libido, Diarrhea, Headache, Impotence, Myalgia, Skin rashes.

Warnings / Precautions

Renal impairment (avoid if severe). MYOTOXICITY.Special care needed in patients with renal disease, as a progressive increase in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolosis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly. Hepatic impairment, liver function tests recommended every 3 months for first year (discontinue treatment if significantly raised). Correct hypothyroidism before initiating treatment.

Interference in Pathology

Fenofibrate may interfere in the diagnosis of Increased in Serum Aminotransferase.

Available Brands

Click on a strength to view available brands.

Multi-Ingredient Combinations

Caps

Storage Conditions

Fenofibrate should be stored Caps.

Drug Classification

  1. 1.12.6Lipid-regulating drugs /Anti-atheromas

Manufacturers